Melanoma in 2017: Moving treatments earlier to move further forwards

Nat Rev Clin Oncol. 2018 Feb;15(2):75-76. doi: 10.1038/nrclinonc.2017.183. Epub 2017 Nov 28.

Abstract

In 2017, results from phase III trials demonstrated the impressive safety and efficacy of adjuvant targeted and immune therapies in patients with resectable stage III–IV melanoma, and raised questions about the surgical management of patients with microscopic sentinel-lymph-node metastases. For patients with unresectable disease, new overall survival data added to the debate about the relative benefits of single-agent anti-PD-1 versus combined anti-PD-1 and anti-CTLA-4 immunotherapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Clinical Trials, Phase III as Topic
  • Humans
  • Imidazoles / adverse effects
  • Imidazoles / therapeutic use*
  • Immunotherapy / trends*
  • Lymphatic Metastasis
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Melanoma / pathology
  • Neoplasm Staging
  • Oximes / adverse effects
  • Oximes / therapeutic use*
  • Progression-Free Survival
  • Pyridones / administration & dosage
  • Pyridones / therapeutic use*
  • Pyrimidinones / administration & dosage
  • Pyrimidinones / therapeutic use*
  • Sentinel Lymph Node / drug effects
  • Sentinel Lymph Node / pathology

Substances

  • Imidazoles
  • Oximes
  • Pyridones
  • Pyrimidinones
  • trametinib
  • dabrafenib